Fennec Pharmaceuticals Inc. FRX.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · United States · fennecpharma.com
Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company headquartered in Research Triangle Park, North Carolina, focused on PEDMARK® (sodium thiosulfate injection), an FDA-approved therapy for reducing cisplatin-induced hearing loss in pediatric patients with solid tumors. The company's shares trade on both the NASDAQ (FENC) and the Toronto Stock Exchange (FRX).
Key ratios
FreeCashFlowOnSale TTM -0.28
FreeCashFlowOnSale 2025 -0.28
FreeCashFlowOnSale 2024 0.57
FreeCashFlowOnSale 2023 -0.81
NetIncomeMargin TTM -0.22
NetIncomeMargin 2025 -0.22
NetIncomeMargin 2024 -0.01
NetIncomeMargin 2023 -0.76
ReturnOnAssets TTM -0.07
ReturnOnAssets 2025 -0.07
ReturnOnAssets 2024 0.04
ReturnOnAssets 2023 -0.3
ReturnOnEquity TTM -0.66
ReturnOnEquity 2025 -0.66
Recent news
Fennec Announces Results of Annual Meeting
2026-06-10 · GlobeNewswire
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 · GlobeNewswire